| Literature DB >> 30417108 |
Lili Ren1, Rongbao Zhang2, Jian Rao1, Yan Xiao1, Zhao Zhang2, Bin Yang1, Depan Cao1, Hui Zhong1, Pu Ning2, Ying Shang2, Mingkun Li3,4,5, Zhancheng Gao2, Jianwei Wang1.
Abstract
Alteration of the lung microbiome has been observed in several respiratory tract diseases. However, most previous studies were based on 16S ribosomal RNA and shotgun metagenome sequencing; the viability and functional activity of the microbiome, as well as its interaction with host immune systems, have not been well studied. To characterize the active lung microbiome and its associations with host immune response and clinical features, we applied metatranscriptome sequencing to bronchoalveolar lavage fluid (BALF) samples from 25 patients with chronic obstructive pulmonary disease (COPD) and from nine control cases without known pulmonary disease. Community structure analyses revealed three distinct microbial compositions, which were significantly correlated with bacterial biomass, human Th17 immune response, and COPD exacerbation frequency. Specifically, samples with transcriptionally active Streptococcus, Rothia, or Pseudomonas had bacterial loads 16 times higher than samples enriched for Escherichia and Ralstonia. These high-bacterial-load samples also tended to undergo a stronger Th17 immune response. Furthermore, an increased proportion of lymphocytes was found in samples with active Pseudomonas. In addition, COPD patients with active Streptococcus or Rothia infections tended to have lower rates of exacerbations than patients with active Pseudomonas and patients with lower bacterial biomass. Our results support the idea of a stratified structure of the active lung microbiome and a significant host-microbe interaction. We speculate that diverse lung microbiomes exist in the population and that their presence and activities could either influence or reflect different aspects of lung health. IMPORTANCE Recent studies of the microbiome proposed that resident microbes play a beneficial role in maintaining human health. Although lower respiratory tract disease is a leading cause of sickness and mortality, how the lung microbiome interacts with human health remains largely unknown. Here we assessed the association between the lung microbiome and host gene expression, cytokine concentration, and over 20 clinical features. Intriguingly, we found a stratified structure of the active lung microbiome which was significantly associated with bacterial biomass, lymphocyte proportion, human Th17 immune response, and COPD exacerbation frequency. These observations suggest that the microbiome plays a significant role in lung homeostasis. Not only microbial composition but also active functional elements and host immunity characteristics differed among different individuals. Such diversity may partially account for the variation in susceptibility to particular diseases.Entities:
Keywords: airborne microorganisms; bacterial biomass; lung microbiome; lung microbiota; metatranscriptome; microbial communities
Year: 2018 PMID: 30417108 PMCID: PMC6208642 DOI: 10.1128/mSystems.00199-18
Source DB: PubMed Journal: mSystems ISSN: 2379-5077 Impact factor: 6.496
FIG 1Diversity and composition of the lung microbiome at the genus level. (A) Alpha diversity values for COPD patients and non-COPD controls. (B) Violin plot of the active lung microbiome composition; only genera with a mean read abundance of at least 5% are shown; thickness indicates the density of the value, and each white dot indicates the median value.
FIG 2Comparison of microbiome composition between metatranscriptome data and 16S rRNA data. (A) Overlap of identified genera between two data sets. (B) The read abundance of the top 10 most abundant genera in 16S rRNA data in two data sets. (C) The read abundance of the top 10 most abundant genera in metatranscriptome data in two data sets. (D) Correlation of the read abundance of each genus between the two methods at the individual level. Red dots denote the genus detected in patient COPD38, who had the highest metatranscriptome-versus-16S rRNA correlation (rho = 0.99, P < 0.001). For display, an abundance of 0 was converted to 10−6.
FIG 3Structure of the lung microbiome at the genus level. (A) Principal-coordinate-analysis (PCoA) plot of the active lung microbiome inferred from metatranscriptome data. Core microbes are labeled on the plot, and the pairwise distance is represented by the Jensen-Shannon divergence (JSD) value. (B) Read abundance of the core microbes in different individuals; samples are ordered by the subgroups to which they belong.
Tests of the association between the structure of the active lung microbiome and clinical features
| Phenotype | Range or results | |
|---|---|---|
| COPD | {Yes, no} | 0.129 |
| Smoking category | {Smoker, quit, never} | 0.338 |
| Smoking amount, range | [0, 60] | 0.229 |
| Inflammation | {Yes, no, unclear} | 0.487 |
| Gender | {Male, female} | 0.378 |
| Location | {Left lower lobe, left lingular lobe, right middle lobe} | 0.631 |
| Age range (yrs) | [28, 83] | 0.355 |
| Smear test | {Positive, negative} | 0.019 |
| Inhaled corticosteroids | {Yes, no} | 0.731 |
| Bronchodilators | {Yes, no} | 0.553 |
| Exacerbation time | [0, 3] | 0.819 |
| Macrophage | [0, 100%] | 0.153 |
| Lymphocyte (%) | [0, 100%] | 0.021 |
| Neutrophil (%) | [0, 100%] | 0.896 |
| FEV1 | [28.3, 99.3] | 0.593 |
| FEV1FVC | [34.4, 70.13] | 0.650 |
| RV/TLC | [5.2, 88.6] | 0.476 |
| CAT | [2, 23] | 0.057 |
| mMRC | {0, 1, 2, 3} | 0.904 |
| Severity score (GOLD) | {1, 2, 3, 4} | 0.3628 |
| Exacerbation frequency | {0.4, 2, 3.5} | 1.3e−5 |
Use of inhaled corticosteroids and bronchodilators in the previous 3 months prior to the bronchoscope examination was considered. Antibiotics were not used at least 8 weeks preceding the bronchoscopy. CAT, COPD assessment test; FEV1, median forced expiratory volume in 1 s; FVC, forced vital capacity; mMRC, modified Medical Research Council dyspnea scale; RV, residual volume; TLC, total lung capacity;
Data represent numbers of packs of cigarettes smoked per year.
Inflammation status was judged by clinician during bronchoscopy.
Data represent numbers of exacerbations during the year preceding the bronchoscopy.
Cells in the BALF were collected and stained with Wright Giemsa’s stain, and cells were counted under a microscope.
GOLD, Global Initiative for Obstructive Lung Disease criteria.
Data represent frequencies of exacerbations for COPD patients in the previous 4 years (2014 to 2018) after the collection of BALF samples.
For discrete data, the contingency table was created and the Fisher exact test was used for the significance test; thus, we were testing whether a specific classification (e.g., male or female) was associated with one of the three active lung microbiome subgroups.
For continuous data, the Kruskal-Wallis rank sum test was applied; thus, we were testing whether a given feature was different among three different active lung microbiome subgroups.
For frequency data, the chi-square test was used for the significance test; thus, we were testing whether the events were randomly distributed in different active lung microbiome subgroups.
Braces mean all possible elements are given here (discrete variable). Square brackets mean a range is given here, e.g., from 0 to 60 (including 0 and 60)(continuous variable).
FIG 4Association between the lung microbiome and clinical features. (A) Bacterial smear test results for different microbiome subgroup samples. (B) Ratio of bacteria reads to human reads. (C) Quantification of bacteria DNA. (D) Proportion of lymphocytes in BALF samples. (E) Proportion of macrophages in BALF samples. (F) Correlation between the proportion of lymphocytes and the read abundance of bacterial genus Bordetella; black dots denote samples in subgroup III. The box plot shows the lymphocyte proportion in Bordetella-positive samples and Bordetella-negative samples.
FIG 5Exacerbation frequency in 21 COPD patients during 2014 to 2018. GOLD (Global Initiative for Obstructive Lung Disease) criteria were used to assess disease severity. A score of “A” represents the mild stage, and a score of “D” represents the most severe stage. Types were defined by microbial composition.
FIG 6Enrichment of KEGG pathways in microbial genes in different samples. (A) Comparison between subgroup I and subgroup II. (B) Comparison between subgroup I and subgroup III. (C) Comparison between subgroup II and subgroup III. Only pathways with P values of <0.01 and q values of <0.1 (Mann-Whitney U test) are shown. The pathways were sorted by their fold changes in different subgroups (increasing from top to bottom). Red boxes represent subgroup I samples, blue boxes represent subgroup II samples, and green boxes represent subgroup III samples.
FIG 7Activation of the Th17 cell differentiation pathway in humans. (A) Expression pattern of 13 key genes involved in Th17 cell differentiation. Differentially expressed genes are indicated in red (P < 0.05). (B) Correlation between the expression of IL-6 and downstream genes in the pathway (STAT3, RORC, and IL17A). The correlation coefficients (rho) were 0.641, 0.578, and 0.681, respectively (P < 0.001). The gene expression level was calculated as log2(normalized number of transcripts per million [TPM] + 0.00001).